dasatinib + nilotinib + ponatinib

dasatinib + nilotinib + ponatinib refers to a nonstandard, multi–tyrosine kinase inhibitor regimen combining three oral BCR-ABL1 tyrosine kinase inhibitors that are individually approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia. Each agent is a small-molecule ATP-competitive inhibitor of BCR-ABL1 with distinct kinase selectivity and toxicity profiles; dasatinib is also a potent SRC family kinase inhibitor, nilotinib is a more selective second-generation ABL inhibitor structurally derived from imatinib, and ponatinib is a third-generation inhibitor uniquely active against BCR-ABL1 T315I and many other resistant mutations.[1][4][9][10][11] This triple combination is not an approved fixed-dose product and would be considered an off-label, high-intensity experimental approach aimed at maximally suppressing BCR-ABL1 signaling across a broad spectrum of resistance mutations, but it carries substantial overlapping risks of myelosuppression, arterial and venous occlusive events, and other class-specific toxicities, so its use would generally be confined to highly selected research settings.[1][4][7][8][10][11]